NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina on behalf of all persons or entities who purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 through October 17, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the fe ...

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). Investo ...

SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024. Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations:  ...

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte secur ...

SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v. Humacyte, Inc., et al., alleges that the company misled investors about the status of its Biologic License Application (BLA) for its acellular tissue engineered vessel (ATEV) and the regulatory compliance of its manufacturing facilities. Hagens Berman urges in ...

- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology’s Kidney Week 2024 - - Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict were presented at the U.S. Department of Defense’s foremost scientific meeting - - ...

DURHAM, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2024, on Friday, November 8, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Title:Humacyte Third Quar ...

Core Insights - Humacyte, Inc. announced positive results from the V007 Phase 3 clinical trial of its acellular tissue engineered vessel (ATEV) for hemodialysis access, demonstrating superiority over the current standard of care, autogenous fistula, at six and twelve months [1][2][3] Clinical Trial Results - The ATEV showed functional patency rates of 81.3% at six months and 68.3% at twelve months, compared to 66.4% and 62.2% for the AV fistula, respectively [3][4] - The trial involved 242 hemodialysis patients, with a statistically significant joint test for superiority of ATEV versus AV fistula (p=0.0071) [3][4] - ATEV patients experienced a longer duration of hemodialysis over the first twelve months compared to AV fistula patients (p=0.0162) [3] Subgroup Analysis - In female patients (n=70), ATEV had significantly higher six-month and one-year patency rates compared to AV fistula (p<0.0001) and a longer duration of hemodialysis (8.3 months vs. 5.0 months, p=0.0011) [4] - In obese patients (n=93), ATEV also showed significantly higher patency rates and longer duration of hemodialysis (7.7 months vs. 4.5 months, p=0.0020) [4] - Diabetic patients (n=165) receiving ATEV had higher patency rates and longer duration of hemodialysis compared to AV fistula (7.4 months vs. 5.5 months, p=0.0155) [4] Safety Profile - Infection rates were low in both treatment arms, with 9.1% of ATEV patients experiencing access-related infections compared to 9.9% for AV fistula [5] - Treatment-Emergent Adverse Events (TAEEs) occurred in 98.3% of ATEV patients, with thrombosis being the most significant adverse event at 52.1% [5] Company Overview - Humacyte is focused on developing bioengineered human tissues and has a portfolio of ATEVs in late-stage clinical trials targeting various vascular applications [7] - The ATEV has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and is under review for a Biologics License Application for vascular trauma [7]

NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of Humacyte stockholders. Our investigation concerns whether Humacyte has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 9, 2024, Humacyte disclosed that the U.S. Food and Drug Adm ...

Humacyte, Inc. (HUMA) closed the most recent trading day at $5.82, moving +1.75% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.22%. On the other hand, the Dow registered a loss of 0.33%, and the technology-centric Nasdaq increased by 0.76%.The the stock of company has risen by 4.86% in the past month, leading the Medical sector's loss of 3.79% and the S&P 500's gain of 1.47%.Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in ...